GAINESVILLE, Fla. (March 10, 2016) – Exactech Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for extremities, knee, hip, spine and biologic materials, announced today that it has completed the requirements of its five-year Corporate Integrity Agreement (CIA) between the Office of Inspector General and the Department of Health and Human Services.
“We are pleased to have completed the requirements of the CIA,” said Exactech Chief Executive Officer David Petty. “Maintaining the highest standards of ethics and compliance is an integral part of our corporate culture and we will continue to honor this commitment through comprehensive, effective and efficient compliance programs.”
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech Inc. can be found at https://aigrenoble.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at https://aigrenoble.com andhttps://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
Executive Vice President of Finance & Chief Financial Officer
Julie Marshall or Frank Hawkins
Vice President, Corporate & Marketing Communication